Many other types of CCR5 antagonists and inhibitors such as Vicriviroc, TAK-779, Met-CCL5 (Met-RANTES), OTR4120, OTR4131, anibamine, and DT-13 were also reported to inhibit the cell migration, invasion and/or metastasis of various malignancies including breast cancer, gastric cancer, pancreatic cancer and hepatocellular carcinoma in preclinical studies [34, 69]. This evidence concerns the gene CCR5 and breast carcinoma.